Services

Custom chemical syntheses and analyses

Consulting and advisory services for academic, commercial, government, and legal clients

Public education services including seminars, publications, conferences, podcasts, symposiums, and training programs
Project Timeline
Year One
- Construct, equip, and staff the modern Shulgin Research Laboratory
- Synthesis of novel lysergamides, tryptamines, and phenylalkylamines as potential psychedelic agents, therapeutic agents, and “nonhallucinogenic psychedelics”
- Cultivation, harvesting, and extraction of plant species to isolate and examine minor alkaloids and other components for their ability to modulate psychoactive effects
- Catalog/characterize existing and unpublished compounds from the Shulgin Vault
- IP protection
Year Two
- Synthesis of PiHKAL and TiHKAL variants and other lead compounds
- Begin in vitro characterization of the Shulgin Vault, newly synthesized, and isolated plant compounds: receptor binding screens and functional assays
- Begin in vivo assays: mouse head-twitch response, Porsolt swim test, locomotor activity
- Begin Phase 1 clinical research with existing but little-explored compounds
- Supply lead compounds to clinical researchers for Phase 1 and Phase 2 medical research
- Structure-activity analyses
Year Three
- Supply compounds to business partners and joint ventures for commercial development
- Continue synthesis, chemical analysis, and biochemical characterization of new substances based on lead compounds: phenylalkylamine, tryptamines, lysergamides
- Continue in vitro and in vivo characterization of the Shulgin Vault, newly synthesized, and isolated plant compounds
- Continue Phase 1 clinical research
- Ongoing: consulting, advisory, and educational services